利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.022 秒)

    Automated contacts book
    1.
    发明授权
    Automated contacts book 有权

    公开(公告)号：US10356042B1

    公开(公告)日：2019-07-16

    申请号：US15974723

    申请日：2018-05-09

    申请人： Roderick Mackenzie-Smith

    发明人： Roderick Mackenzie-Smith

    IPC分类号： H04L29/12 ,  H04M1/2745

    摘要： A system, method or computer program product for providing automated contacts books can include an automated contacts book application and a contact details server. The automated contacts book application can run on a computer or mobile computing device and can be configured to interface with the contact details server so that users of the automated contacts book can search for and connect with other users within the contact details server. The automated contacts book can be further configured to permit each user remotely to populate, update and manage availability of their contact details in the automated contacts book applications of all the other users with whom the user is connected within the contact details server. The automated contacts book application can be further configured to interface with the communications systems of the computing devices on which it runs so as to use the up-to-date contact details to send communications.

    (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
    3.
    发明授权
    (Azetidin-1-ylalkyl) lactams as tachykinin antagonists 失效
    （氮杂环丁烷-1-基烷基）内酰胺作为速激肽拮抗剂

    公开(公告)号：US5968923A

    公开(公告)日：1999-10-19

    申请号：US798534

    申请日：1997-02-10

    申请人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    发明人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    IPC分类号： C07D205/08 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/451 ,  A61K31/4523 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/535 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61P1/00 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61P43/00 ,  C07D205/04 ,  C07D205/06 ,  C07D205/085 ,  C07D211/76 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06 ,  C07D521/00 ,  A61K401/06 ,  A61K413/14 ,  A61K451/02

    CPC分类号： C07D231/12 ,  C07D211/76 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D451/02

    摘要： The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C.sub.3 -C.sub.7 cycloalkyl, aryl or C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl, said C.sub.1 -C.sub.6 alkyl being optionally substituted by fluoro, COOH, --COO(C.sub.1 -C.sub.4 alkyl), C.sub.3 -C.sub.7 cycloalkyl, adamantyl, aryl or het.sup.1, and said C.sub.3 -C.sub.7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, fluoro, fluoro (C.sub.1 -C.sub.4) alkyl and fluoro (C.sub.1 -C.sub.4) Alkoxy; R.sub.1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo and trifluormethyl; R.sup.2 is --CO.sub.2 H, --CONR.sup.3 R.sup.4, --CONR.sup.5 (C.sub.3 -C.sub.7 cycloalkyl), --NR.sup.5 (C.sub.2 -C.sub.5 alkanoyl), --NR.sup.3 R.sup.4, --NR.sup.5 CONR.sup.5 R.sup.6, (C.sub.3 -C.sub.7 cycloalkyl-C.sub.1 -C.sub.4 alkyl)R.sup.5 N--, --NR.sup.5 COCF.sub.3, --NR.sup.5 SO.sub.2 CF.sub.3, --NR.sup.5 (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --NR.sup.5 SO.sub.2 NR.sup.5 R.sup.6, --NR.sup.5 (SO.sub.2 aryl), --N(aryl) (SO.sub.2 C.sub.1 -C.sub.4 alkyl), --OR.sup.5, --O(C.sub.3 -C.sub.7 cycloalkyl), --SO.sub.2 NR.sup.5 R.sup.6, het.sup.3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C.sub.1 -C.sub.4 alkylene; X.sup.1 is a direct link or C.sub.1 -C.sub.6 alkylene; X.sup.2 is a direct link, CO, SO.sub.2, or NR.sup.5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. ##STR1##

    摘要翻译： PCT No.PCT / EP95 / 03054 Sec。 371日期1997年2月10日 102（e）日期1997年2月10日PCT提交1995年7月29日PCT公布。 出版物WO96 / 05193 日期：1996年2月22日本发明提供式（I）化合物及其药学上可接受的盐，其中R为C 3 -C 7环烷基，芳基或C 1 -C 6烷基，所述C 1 -C 6烷基，所述C 1 -C 6烷基任选 被氟，COOH，-COO（C1-C4烷基），C3-C7环烷基，金刚烷基，芳基或het1取代，所述C3-C7环烷基任选被1或2个独立地选自C 1 -C 4烷基，C 3 C 1 -C 4烷氧基，羟基，氟，氟（C 1 -C 4）烷基和氟（C 1 -C 4）烷氧基; R1是苯基，萘基，噻吩基，苯并噻吩基或吲哚基，各自任选被1或2个独立地选自C 1 -C 4烷基，C 1 -C 4烷氧基，卤素和三氟甲基的取代基取代; R2是-CO2H，-CONR3R4，-CONR5（C3-C7环烷基），-NR5（C2-C5烷酰基），-NR3R4，-NR5CONR5R6，（C3-C7环烷基-C1-C4烷基）R5N-，-NR5COCF3， NR5SO2CF3，-NR5（SO2 C1-C4烷基），-NR5SO2NR5R6，-NR5（SO2芳基），-N（芳基）（SO2C1-C4烷基），-OR5，-O（C3-C7环烷基），-SO2NR5R6， 或（a），（b），（c），（d），（e），（f），（g）或（h） X是C 1 -C 4亚烷基; X1是直链或C1-C6亚烷基; X2是直接连接，CO，SO2或NR5CO; m为0,1或2; 以及用于制备含有这种衍生物的速激肽类似物的组合物中使用的中间体。

    Benzopyrans
    4.
    发明授权
    Benzopyrans 失效
    苯并吡喃

    公开(公告)号：US5912244A

    公开(公告)日：1999-06-15

    申请号：US591500

    申请日：1996-07-08

    申请人： Alexander Roderick MacKenzie ,  Sandra Marina Monaghan

    发明人： Alexander Roderick MacKenzie ,  Sandra Marina Monaghan

    IPC分类号： A61K31/35 ,  A61K31/352 ,  A61K31/44 ,  A61K31/443 ,  A61K31/50 ,  A61K31/505 ,  A61P1/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  C07D311/70 ,  C07D403/04 ,  C07D405/12 ,  C07D493/04 ,  C07F7/18 ,  C07D311/22 ,  C07D237/14 ,  C07D239/32 ,  C07D241/02

    CPC分类号： C07D403/04 ,  C07D311/70 ,  C07D405/12 ,  C07F7/1856

    摘要： A compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein X is O, S or NH;R and R.sup.1 are each independently selected from H and C.sub.1 -C.sub.4 alkyl or taken together represent C.sub.2 -C.sub.6 alkylene;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl;R.sup.3 is a 6-membered heterocyclic ring containing 2N hetero-atoms, said ring being linked to X by a ring carbon atom, optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by C.sub.1 -C.sub.6 alkyl, hydroxy, --OR.sup.5, halo, --S(O).sub.m R.sup.5, oxo, amino, --NHR.sup.5, --N(R.sup.5).sub.2, cyano, --CO.sub.2 R.sup.5, --CONH.sub.2, --CONHR.sup.5 or --CON(R.sup.5).sub.2, with the proviso that R.sup.3 is not an N--(C.sub.1 -C.sub.6 alkyl)pyridonyl group;R.sup.4 is phenyl substituted by a hydroxy group and optionally further substituted by 1 or 2 substitutents each independently selected from hydroxy, C.sub.1 -C.sub.6 alkyl, --OR.sup.5, halo, cyano and nitro;R.sup.5 is C.sub.1 -C.sub.6 alkyl;R.sup.6 is --OR.sup.5, --NHR.sup.5, --N(R.sup.5).sub.2, --SR.sup.5 or --NHR.sup.9 ;R.sup.7 is cyano;R.sup.8 is --OR.sup.5, --NHR.sup.5, --N(R.sup.5).sub.2, or --NHR.sup.9 ;R.sup.9 is phenyl optionally substituted by C.sub.1 -C.sub.6 alkyl, hydroxy, --OR.sup.5, halo, cyano or nitro; andm is 0, 1 or 2.

    摘要翻译： PCT No.PCT / EP94 / 02387第 371日期：1996年7月8日 102（e）日期1996年7月8日PCT 1994年7月18日PCT公布。 公开号WO95 / 04730 日期：1995年2月16日具有下式的化合物或其药学上可接受的盐，其中X为O，S或NH; R和R 1各自独立地选自H和C 1 -C 4烷基或一起代表C 2 -C 6亚烷基; R2是H或C1-C4烷基; R3是含有2N个杂原子的6元杂环，所述环通过环碳原子与X连接，任选苯并稠合并任选被取代，包括苯并稠合部分中的C 1 -C 6烷基，羟基， -OR 5，卤代，-S（O）m R 5，氧代，氨基，-NHR 5，-N（R 5）2，氰基，-CO 2 R 5，-CONH 2，-CONHR 5或-CON（R 5）2， 不是N-（C 1 -C 6烷基）吡啶酮基; R4是被羟基取代的苯基，并任选进一步被1或2个取代基取代，各自独立地选自羟基，C 1 -C 6烷基，-OR 5，卤素，氰基和硝基; R5是C1-C6烷基; R6是-OR5，-NHR5，-N（R5）2，-SR5或-NHR9; R7是氰基; R8是-OR5，-NHR5，-N（R5）2或-NHR9; R9为任选被C 1 -C 6烷基，羟基，-OR 5，卤素，氰基或硝基取代的苯基; m为0,1或2。

    3-aza and 3-oxa piperidone tachykinin antagonists
    5.
    发明授权
    3-aza and 3-oxa piperidone tachykinin antagonists 失效
    3-氮杂和3-氧杂哌啶酮速激肽拮抗剂

    公开(公告)号：US5846965A

    公开(公告)日：1998-12-08

    申请号：US788001

    申请日：1997-01-24

    申请人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    发明人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Sandra Dora Meadows ,  Donald Stuart Middleton

    IPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/535 ,  A61K31/5355 ,  A61P1/00 ,  A61P11/00 ,  A61P13/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  A61P25/28 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D403/06 ,  C07D413/06 ,  A61K31/395 ,  C07D205/04 ,  C07D243/08 ,  C07D403/14

    CPC分类号： C07D403/06 ,  C07D413/06

    摘要： Compounds of the formula: ##STR1## wherein: X is O, NH or NR.sup.1 ; R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alkyl, aryl or aryl (C.sub.1 -C.sub.4)alkyl; wherein the C.sub.1 -C.sub.6 alkyl group is optionally substituted by fluorine and the C.sub.3 -C.sub.7 cycloalkyl or C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4 )alkyl group is optionally substituted in the cycloalkyl ring by up to two substituents each independently selected from halo, C.sub.1 -C.sub.4 alkoxy or halo(C.sub.1 -C.sub.4)alkoxy; R.sup.2 is phenyl optionally substituted with one or two halo substituents, indolyl or thienyl; R.sup.3 is NH.sub.2, --NR.sup.4 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --NR.sup.4 SO.sub.2 aryl, --NR.sup.4 CO(C.sub.1 -C.sub.6 alkyl), --NR.sup.4 CO aryl or a 5 to 7-membered N-linked cyclic group incorporating W in the ring wherein W is O, NR.sup.5, CH(OH), CHCO.sub.2 H, CHN(R.sup.4).sub.2, CHF, CF.sub.2, C.dbd.O or CH.sub.2 ; R.sup.4 is H or C.sub.1 -C.sub.6 alkyl; R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl, C.sub.2 -C.sub.6 alkanoyl, C.sub.4 -C.sub.8 cycloalkanoyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.2 -C.sub.6)alkanoyl, aryl CO--, C.sub.1 -C.sub.6 alkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl SO.sub.2 --, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.6)alkyl SO.sub.2 --, aryl-SO.sub.2 -- or (R.sup.6).sub.2 NSO.sub.2 --, wherein each R.sup.6 is independently H or C.sub.1 -C.sub.4 alkyl or the two groups may be joined to form with the nitrogen atom to which they are attached, a pyrrolidinyl, piperidino, morphlino or piperazinyl group; m is 0, 1 or 2 with the proviso that m is not 0 when W is NR.sup.5, C.dbd.O, or O; and n is an integer of from 1 to 4; are neurokinin receptor antagonists of utility in the treatment of a variety of medical conditions including urinary incontinence, asthma and related conditions.

    摘要翻译： 下式的化合物：其中：X是O，NH或NR1; R1是C1-C6烷基，C3-C7环烷基，C3-C7环烷基（C1-C4）烷基，芳基或芳基（C1-C4）烷基; 其中C 1 -C 6烷基任选被氟取代，并且C 3 -C 7环烷基或C 3 -C 7环烷基（C 1 -C 4）烷基任选在环烷基环中被至多两个各自独立地选自卤素， C4烷氧基或卤代（C1-C4）烷氧基; R2是任选被一个或两个卤素取代基取代的苯基，吲哚基或噻吩基; R 3是NH 2，-NR 4 SO 2（C 1 -C 6烷基），-NR 4 SO 2芳基，-NR 4 CO（C 1 -C 6烷基），-NR 4 CO芳基或在其中W为W的5至7元N-连接的环状基团 O，NR 5，CH（OH），CHCO 2 H，CHN（R 4）2，CHF，CF 2，C = O或CH 2; R4是H或C1-C6烷基; R5是H，C1-C6烷基，C3-C7环烷基，C3-C7环烷基（C1-C6）烷基，C2-C6烷酰基，C4-C8环烷酰基，C3-C7环烷基（C2-C6）烷酰基，芳基CO-， C 1 -C 6烷基SO 2 - ，C 3 -C 7环烷基SO 2 - ，C 3 -C 7环烷基（C 1 -C 6）烷基SO 2 - ，芳基-SO 2 - 或（R 6）2 NSO 2 - ，其中每个R 6独立地是H或C 1 -C 4烷基或 两个基团可以与它们所连接的氮原子结合形成吡咯烷基，哌啶子基，吗啉基或哌嗪基; m为0,1或2，条件是当W为NR5，C = O或O时，m不为0; n为1〜4的整数， 是用于治疗各种医学状况（包括尿失禁，哮喘和相关病症）的神经激肽受体拮抗剂。

    SNOW TRACTION UNIT FOR VEHICLES
    7.
    发明申请
    SNOW TRACTION UNIT FOR VEHICLES 有权
    用于车辆的SNOW牵引单元

    公开(公告)号：US20100219004A1

    公开(公告)日：2010-09-02

    申请号：US12303743

    申请日：2007-06-08

    申请人： Roderick Mackenzie

    发明人： Roderick Mackenzie

    IPC分类号： B62D55/18 ,  B62D55/092

    CPC分类号： B62D55/04 ,  B62D55/065 ,  B62D55/084 ,  B62D55/10 ,  B62D55/125 ,  B62D55/20

    摘要： A snow traction unit to replace a wheel of an all wheel drive vehicle which includes a frame supporting two carrier wheels; said carrier wheels being spaced apart a distance greater than their combined radii; an endless snow contacting track mounted for rotation on said carrier wheels; a track contacting surface provided between the lower extremities of said carrier wheels; a drive engagement means for engaging the drive shaft of the vehicle and for driving at least one of said carrier wheels; the arrangement of the width of the track, the spacing between the carrier wheels and the track contacting surface resulting in the vehicle having a force imprint less than 250 Kg/square metre.

    摘要翻译： 一种雪地牵引单元，用于更换包括支撑两个承载轮的框架的全轮驱动车辆的车轮; 所述承载轮间隔开大于其组合半径的距离; 一个安装在所述承载轮上旋转的无尽的雪地接触轨道; 设置在所述承载轮的下肢之间的轨道接触表面; 用于接合车辆的驱动轴并用于驱动至少一个所述承载轮的驱动接合装置; 轨道宽度的布置，承载轮和轨道接触表面之间的间距，导致车辆的力压印小于250Kg /平方米。

    Piperidone tachykinin antagonists
    10.
    发明授权
    Piperidone tachykinin antagonists 失效
    哌啶酮速激肽拮抗剂

    公开(公告)号：US06262075B1

    公开(公告)日：2001-07-17

    申请号：US09117011

    申请日：1998-07-20

    申请人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Donald Stuart Middleton ,  Sandra Dora Meadows

    发明人： Alexander Roderick MacKenzie ,  Allan Patrick Marchington ,  Donald Stuart Middleton ,  Sandra Dora Meadows

    IPC分类号： A61K31454

    CPC分类号： C07D401/14

    摘要： The present invention provides compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein X is a direct link or C1-C4 alkylene; and R is C3-C7 cycloalkyl optionally substituted by 1 or 2 substituents each independently selected from fluoro and C3-C7 cycloalkyl: with the proviso that X is not methylene when R is cyclopropyl, together with processes for the preparation of, intermediates used in the preparation of, compositions containing and uses of, such compounds. These compounds are useful as tachykinin antagonists.

    摘要翻译： 本发明提供式（I）化合物及其药学上可接受的酸加成盐，其中X为直链或C1-C4亚烷基; 并且R是任选被1或2个独立地选自氟和C 3 -C 7环烷基的取代基取代的C 3 -C 7环烷基：条件是当R是环丙基时，X不是亚甲基，以及制备用于 含有和使用这些化合物的组合物的制备。 这些化合物可用作速激肽拮抗剂。